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Abstract: The high quality of public health improves not only healthy life expectancy, but 
also the productivity of labor. The most important part of the health care sector is the medical 
technology industry. The aim of this study is to analyze the current situation in the medical device 
industry in Europe, its potential strengths and weaknesses in the context of topical economic 
and demographic development. The contribution specifies an analysis of the economic state of 
the medical device industry in the context of demographic development of European Union’s 
macroeconomic indicators and views of experts in the field of medical device development, 
concerning the opportunities for entities involved in the medical device market. There is fierce 
competition on the European market. The innovative activity is stable and well regulated by 
responsible authorities. Worldwide, the medical device market is expected to grow.
Keywords: technology context, medical device, Europe, expenditure, review
Introduction
With respect to the demographic trend in Europe, health care and the development 
of health devices are hot issues. Several studies evaluate the prospects of medical 
interventions,1,2 economic effectiveness of innovative technologies in health care,3 or 
Health technology assessment in chosen European countries. In order to implement 
innovative technologies in practice, it is becoming extremely important to be cost con-
scious and effective as well as to know and follow new guidelines in health care.4
Many studies have proved that there is a relation between health and the economic 
development of countries.5–9 Improved public health leads to healthy life expectancy, 
which is then reflected in increased quality and productivity of labor. It is therefore 
vital to invest in the health of working people in order to prolong their active life 
and achieve better health. This investment may also decrease future costs of treating 
patients suffering from preventable diseases. The healthier the individual people are, 
the more and longer they are able to be at the labor market. Approximately one in four 
currently employed people (23.5%) suffers from a chronic condition, which limits them 
in doing their daily activities. It is the more so in latter stages of their lives when their 
participation in the labor market is markedly lower.10 Moreover, there is an increased 
incidence of multiple diseases (comorbidity) at higher age. As a result, the pressure 
on health systems and social care structures in terms of demand for care increases.
In the context of this development, the problem of investments in the medical 
device industry as a part of health care becomes more significant. Medical devices are 
irreplaceable in diagnostics, prevention, monitoring, and medical treatment of diseases 
and in increasing the quality of life of persons with a health problem.11 Variability and 
innovativeness of this industry significantly contribute to an increase in the quality 
and efficiency of health care. The aim of this contribution is to analyze and specify the 
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current situation in the medical device industry, its potential 
strengths and weaknesses in the context of topical economic 
and demographic development.
Research methods
The following methods are used in the issue: retrospective 
analysis (of demographic data, data related to the growth of 
medical device market), structured interviews with experts, 
and analysis of external environment. External analysis 
focuses on the surrounding environment, aims at the oppor-
tunities, threats, as well as other factors that will influence the 
future strategy of this industry. This analysis specifies politi-
cal, economic, social, and technological factors (therefore, 
it is also called PEST analysis). The individual factors are 
arranged according to their importance as for the expected 
future state of the industry. The analysis of political factors 
monitors laws, restrictions, and conditions significant for 
the future development of the industry, including legisla-
tion, political stability, tax policy, and integration policy. 
Among the most important economic factors are gross 
domestic product (GDP), interest rate, or inflation. These 
factors specify the performance of the industry. Social fac-
tors are important, in particular, for companies involved in 
selling products to the end consumer. In this area, it is vital 
to understand demographic stratification, lifestyle, income, 
and religious issues. Technological changes may suddenly 
and dramatically influence the whole industry. Among 
the monitored factors are government support to research 
and development (R&D), general technological level, new 
discoveries, and inventions. The analyses of the external 
environment served as the basis for forming the so-called 
SWOT matrix (strengths, weaknesses, opportunities, and 
threats). The SWOT analysis was devised by Albert Humpley 
in the 1960s. The SWOT analysis process is usually divided 
into three basic stages:
•	 Identification and assessment of strengths and weak-
nesses, which are internal to the organization.
•	 Identification and assessment of opportunities and threats, 
which are external to the organization.
•	 Creating the SWOT matrix.
Strengths are internal resources of the company, its 
positive attributes, or assets. Weaknesses are aspects of the 
organization that need improvement and cause competitive 
disadvantage. Opportunities are external attractive factors 
that the organization can benefit from as they increase 
demand or can better satisfy the customer. Threats include 
external factors and trends beyond control that could decrease 
demand or cause future losses.12,13 In the table are summarized 
SWOT of the given segment. The aim was to achieve the 
greatest possible objectification of the assessment, the 
SWOT analysis was created by a multi-disciplinary and 
international team consisting of a specialist in the develop-
ment of medical devices (two specialists), development of 
pharmaceuticals (one specialist), economy (one specialist), 
and modern technology (three specialists). The role of each 
team member was to describe partial strengths, weaknesses, 
the potential opportunities, and threats in their area of work, 
which corresponded to the individual parts of the analysis of 
external environment. The team members then carried out 
quantified evaluation of each item of the European Union 
(EU) Medical Device Industry according to their significance. 
Factors were assessed on the scale from 1 to 5, where 5 stood 
for the highest significance in relation to the EU countries. 
Each factor was then assigned with significance, that is, the 
numeric representation of the significance of its impact on 
the development in the medical device industry. The sum of 
significance in each category must be equal to 1.
The analysis of external 
environment in the medical device 
industry
The economic situation of the medical 
device industry
In economic terms, the current world witnesses a slow growth 
and in the near future the situation probably will not change 
much. A little increase in economic activities is expected 
and the number of unemployed people will decrease only 
little, if at all. There are still short-term risks represented 
by problems in the Eurozone, the USA have not overcome 
fiscal adjustments, and developing countries’ economies are 
slowing down, even though the situation is getting better. 
Concerning medium-term risks, several developed econo-
mies adopted unconventional and risky monetary measures 
aimed at improving global financial stability.14
In relation to the medical device industry, it may be 
observed that there are unprecedented opportunities loom-
ing for the medical device industry in countries such as the 
People’s Republic of China, India, Latin America, the Middle 
East, and other emerging markets with rising GDP and expand-
ing middle class. The rise in both population and disposable 
income should lead to a much higher demand for medical 
devices and medical services. The expansion of medical device 
companies into developing countries will increase their manu-
facturing efficiency and decrease the price of their products. 
They will also be able to better serve local markets.
The medical technology industry, with its established 
centers in the USA and Western Europe, is becoming a 
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flagship of the whole health care sector. Among other 
things, it manufactures devices facilitating not only pre-
vention, but also diagnosis and the follow-up treatment. 
Nevertheless, the focus of the medical technology industry 
is becoming to move eastward to Asia, particularly to the 
People’s Republic of China, which will probably become 
prominent in the near future.15 The medical device indus-
try comprises thousands of firms, predominantly small 
enterprises with up to 50 employees. The main drivers 
of innovation in this area are start-ups that are usually 
financed by venture capital.4
The USA is currently both the largest producer and the 
consumer of medical devices, with approximately 50% of 
the world market. It is followed by Japan, the EU, Canada, 
and Australia, which boast of large and stable markets with 
medical devices.10 Generally speaking, all developed countries 
witness a significant increase in both production and consump-
tion of medical devices.16 The global market is on the rise not 
only due to higher life expectancy in the developed countries, 
but also because of new markets in developing countries. 
Figure 1 shows an increased interest of survey participants in 
the BRIC (Brazilian, Russian, Indian, and Chinese) markets. 
Another attractive market is the Mexican one due to a new and 
much more efficient regulatory system.17 Brazil is the leading 
country with 20% of small companies, 21% of medium ones, 
and 17% of large companies. It is followed by the People’s 
Republic of China, which is second for both medium and 
large enterprises, India, on the other hand, boasts of a higher 
number of small enterprises than the People’s Republic of 
China, which means an easier way to the Indian market for 
those with lower resources. Some 18% of American firms 
and approximately 19% of EMEA (European, Middle East, 
and African) companies strive to enter the Brazilian market 
this year. Concerning Asia–Pacific companies, 29% of them 
plan to expand into the Chinese market.
The economic situation of the medical device 
industry in europe
Europe boasts of some 25,000 medical technology com-
panies. Most of them have their headquarters in Germany, 
the UK, Italy, Switzerland, Spain, and France. 95% of the 
medical technology industry comprises small and medium-
sized enterprises. Most of them have less than 50 employees. 
Small and micro-sized firms employ some 575,000 people. 
The largest share of medical technology industry employees 
in total employment is in Germany, while the highest number 
of employees in this industry per capita is in Switzerland 
and Ireland. Such high numbers of employees prove that the 
medical technology industry is a significant player in Europe 
and in its economy. Whereas, in the USA the medical technol-
ogy industry provides jobs to approximately 520,000 people, 
the European pharmaceutical industry employs some 675,000 
people. In 2012, there were more than 10,000 registered pat-
ent applications in this field. The annual investment in R&D 
equals approximately 4 billion €19.19. The medical device 
industry belongs to one of the most innovative sectors with 
an average life cycle of only 18 months before an improved 
product becomes available.11
European countries spent on average 10.4% of their 
GDP on health care.1 Approximately 7.5% of it is spent on 
medical technologies. Nevertheless, expenditures on medical 
technologies vary significantly across Europe. They usually 
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Figure 1 interest in the emerging markets.
Note: Data from emergo Group.18
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range between 5% and 10% of total expenditures on health 
care. European per capita expenditure on medical technolo-
gies equals €1,957 (weighted average), whereas in the USA it 
is €380. The average annual growth of the European market 
over the last 6 years is 4%. Figure 2 shows the development 
in individual years. The value of the European medical tech-
nology market is estimated at some €100 billion. Medical 
technologies help solve problems in many areas. Globally, 
the largest segment is in vitro diagnostics, cardiology comes 
second, and diagnostic imaging third.
Technological environment of the medical 
device industry
The technological factors affecting the economic level 
include government support for R&D, the overall level 
status of the use of technologies, as well as, for example, 
new discoveries.19 These three areas will also be focused 
on in connection with the situation in the EU and with 
the medical devices sector. The economic significance 
of innovation activities has been growing. Planned state 
budget R&D expenditures in the years of 2013, 2014, and 
2015 have been approved for €1.036 million per year.20 
Up until 2015, the percentage of financial resources for 
R&D provided as a special-purpose support should be 
rising. These expenditures should correspond to the real 
demand in the application sphere. Institutional support will 
constitute a significant part of public resources for R&D. 
The supported areas will be particularly the transfer of 
knowledge into practice, patenting, or establishing spin-
off companies.
Another key factor of R&D development is risk capital 
investment, which is private investment in companies deal-
ing with the development of new products and technologies, 
usually in the initial phase (start-up and seed) or in the 
expansion phase. The highest level of these investments is in 
Bulgaria, Romania, and Greece. The Czech Republic belongs 
to the category of countries with the lowest risk capital 
investment. Luxemburg disburses by far the most risk capital 
investment, followed by Denmark and Hungary. In the context 
of patent activity, European countries demonstrate re-active 
constant activity. The maximum value was reached in 2008, 
followed by a decline. This development may be affected by 
the economic crisis and a lack of funding in R&D.
The medical technology industry is known for the high 
quality of R&D as well as for its cooperation with end 
users, which leads to continuous innovation. An improved 
version of almost any product is available within 2 years of 
launching the previous model. In 2012, the European Patent 
Office counted more than 10,000-plus patent applications 
in the field of medical technology, which was 7% of all 
patent applications. No other technical field achieved such 
a high figure. European countries filed 38% of all patent 
applications in this field. In order to provide a comparison, 
there were approximately 5,400 patent applications in the 
pharmaceutical industry and 5,300 applications in the area 
of biotechnology. Within the last 10 years, the number of 
European Patent Office medical technology patent applica-
tions has doubled, whereas the number of applications in the 
field of biotechnology and pharmaceutics remained more or 
less stable.21
Political–legal environment
Significance of the political and legal environment for 
entrepreneurship is indisputable. As an indispensable part 
of institutional quality, it directly affects realization and 
efficiency of entrepreneurial activities and total economic 
efficiency. Factors related to power distribution and legislative 
environment are significant in this sector. Government’s and 
other state institutions’ activities may significantly influence 
entrepreneurship on various types of market. This section 
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Figure 2 european medical technology market growth rates, based upon the manufacturer process, 2008–2013.
Note: Data from Medtech europe.1
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describes legislation related to a medical device. Regulations 
in the global market as in the People’s Republic of China, 
Europe, Canada and follow US FDA’s model. Medical 
devices are classified into Classes I, II, and III. Regulatory 
control increases from Class I to Class III. The device clas-
sification regulation defines the regulatory requirements for 
a general device type.
Medical device regulation in the eU
Medical device regulation in the EU is governed by three EU 
council directives and their subsequent amendments:22
•	 90/385/EEC on Active Implantable Medical Devices,
•	 93/42/EEC on Medical Devices,
•	 98/79/EC on In Vitro Diagnostic Medical Devices.
The Directives are supported by guidelines, which, 
according to the European Commission, are aimed at the 
promotion of a:
Common approach by manufacturers and Notified Bodies 
involved in the conformity assessment procedures according 
to the relevant annexes of the Directives, and by the Compe-
tent Authorities charged with safeguarding Public Health.
All medical devices placed on the market in the EU must 
comply with the relevant Directive. The medical device direc-
tive covers a wide range of medical devices, from first-aid 
bandages and walking frames to implantable devices and 
computed tomography scanners. The level of medical device 
assessment therefore varies, according to the perceived risk 
of the device. For medium and high-risk devices, companies 
are required to have their quality systems and technical 
documentation reviewed by a notified body before their 
products can be placed on the market. The notified body has 
a responsibility for ensuring that the relevant requirements 
are met prior to the issue of certification. Manufacturers are 
then able to place the European Conformity (CE) marking 
on their products to demonstrate regulatory compliance. The 
CE marking is recognized throughout the EU, the European 
Economic Area and Switzerland, which allows these prod-
ucts to be sold over this geographically wide area. Nonethe-
less, individual states may request registration of medical 
devices, and may have additional requirements relating to 
the language of the device information. For manufacturers 
of Class I or IVD medical devices, it is a legal requirement 
to provide certain information to a competent authority in 
an EU member state where they have a registered place of 
business, prior to marketing their device in the EU. If the 
company does not have a registered place of business in the 
EU, they must designate someone who is established in the 
EU to act on their behalf.22 Potential sources of financing 
health care and the development of medical devices lie in 
the following funds:23
•	 the European Regional Development Funds, which 
strengthens cohesion, namely economic, social, and 
territorial one, by redressing the balance among various 
regions,
•	 the European Social Funds, which is the main instrument 
of the EU for investing in its citizens,
•	 Horizon 2020.
These programs are relevant and provide investment 
opportunities to complement those financed through Struc-
tural Funds. Furthermore, the Commission strongly promotes 
Public–Private Partnerships as a means of improving the 
levels of investment and innovation in a wide range of public 
services including health care.24
In order to ensure the smooth functioning of a support 
system, it is necessary to have a clear and efficient legisla-
tion, which must be implemented across the whole of the 
EU in a consistent way and which enables quick access to 
the latest technologies.
Social environment
The social and cultural environment is based on demographic 
situation, employment rate, the population’s education and 
income, etc. It is important to monitor the basic values and 
attitudes of the population and specific needs of various target 
groups. The forecast percentage growth in over-65 and over-80 
inhabitants in the EU countries is illustrated in Figure 3.
In developed economies, aging population will drive 
the growth of medical device companies. More than 80% 
of people aged 65 years or above have at least one chronic 
disease. People aged 60 years or above will increase signifi-
cantly 2012 onward when the first wave of those born during 
the baby boom generation begins to turn 65 years, presenting 
great opportunities for medical devices companies that bring 
innovative technologies to address the chronic disease.26 Table 
1 shows figures of university educated citizens with degrees in 
the 30–34 years age group. EU strategy target is to achieve 40% 
by 2020. The demographic trend in EU acts strongly against 
this objective. The Governments of chosen EU countries 
determined the maximum number of accepted students.
Currently, the real income drops, which results in lower 
consumer expenditures and the creation of savings. These 
facts hinder economic growth. Its largest part of income is 
wages. They differ significantly according to economic activ-
ity. The highest income is in finance and insurance, followed 
by the information and communication sectors.
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Figure 3 Aging population.
Note: Data from eurostat.25
Table 1 Total number of people in tertiary education in the eU (%)
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
eU average 22.4 22.8 23.5 25.0 26.9 28.0 28.9 30.0 31.0 32.2 33.5 34.6 35.8
Note: Data from eurostat.25
Abbreviation: eU, european Union.
Social environment in the medical device 
industry
Employment and incomes within the medical device indus-
try is quite complicated to describe. Since the production 
of medical devices is part of the manufacturing industry 
category, it is not monitored separately at an international 
level (Eurostat databases, OECD). According to Eurostat 
and OECD, 15,400 industry professionals are in the 
medical device industry. The median salary grew by 5%, 
to $105,000 between 2012 and 2013. The rising demand 
for employees in the areas of quality and regulatory affairs 
is also reflected in earnings. Salaries for quality assurance 
and quality control professionals increased more than 3% 
in 2013.
The situation of medical device industry – 
SwOT analysis
The aforementioned analysis of external environment (eco-
nomic, legislative, social, and technological) described the 
most significant impacts on the medical device industry. 
Table 2 specifies SWOT in this industry. In the Criterion 
column, the experts assessed the significance of each item 
on the scale from 1 to 5 as it is described in the “Research 
methods” section. On the scale 0–1, the significance was 
given to each item in four categories (strengths, weakness, 
opportunities, and threats) of the SWOT analysis (the sum 
must equal to 1). The Total Impact column was created as 
the product of “Criteria*Significance” (Table 2).
With respect to the aforementioned trends in the medi-
cal device industry, it can be maintained that it is a very 
prospective field. Nevertheless, investments in it may have 
their advantages as well as drawbacks and provide companies 
with many opportunities.
Among the most significant strengths of the medical 
device industry in the EU are, in comparison with other sec-
tors, relatively high expenditures on health care (0.75) and 
medical technologies, an increasing growth in science and 
research expenditures, quality research centers, and qualified 
workforce (0.8).
All factors related to the scattered and dissonant EU 
administration and legislation (0.4) as well as insufficient 
interconnection between scientific research institutions 
and practice (0.72) create obstacles to the growth of this 
 industry’s efficiency. In addition, a very crucial weakness 
is a significant threat to the future when it will be necessary 
to work on improving the cooperation among universities, 
scientific research institutes, and institutions, support-
ing innovative entrepreneurship capacities of science and 
technology parks. In this industry, it is also essential to pay 
attention to the long-run development goals. The continuing 
stagnation of the EU economy (0.1) and underrated R&D 
cooperation in clusters (0.85) were marked as a threat with 
relatively smaller significance.
Future opportunities in the medical device industry is 
aging population (1) and clear vision (0.4) in developed 
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Table 2 SwOT analysis of the eU medical device industry
Criterion Significance Total impact
Strengths
High expenditures on health care, particularly on medical technologies 5 0.15 0.75
well-developed industry with a strong manufacturing base 3 0.08 0.24
Macroeconomic and price stability of the sector 2 0.05 0.1
Quality research centers 4 0.15 0.6
increasing annual growth of science and research expenditures 4 0.12 0.48
Existing qualified workforce 4 0.2 0.8
existing strategic development goals 4 0.1 0.4
existing and new business incubators and science and technology research parks 3 0.1 0.3
Growth of the medical device industry 4 0.05 0.2
Total 1
Weaknesses
Disunited legislative environment in eU countries 4 0.1 0.4
Administratively demanding system of public support 4 0.08 0.32
Fragmented consultancy in the fields of public support subsidies and legislation 3 0.1 0.3
A lack of strong linkages between industries and academia 4 0.18 0.72
Insufficient coordination and standardization of the medical device industry development 3 0.12 0.36
Uncooperative research centers 3 0.17 0.51
Legislative difficulties of transferring scientific results in company practice 4 0.1 0.4
Low utilization of risk capital to financing 2 0.1 0.2
Total 1
Opportunities
Favorable demographics, namely an aging population in the developed world and a higher  
number of active elderly people will lead to an increase in demand for medical devices  
and medical services
5 0.2 1
Medical device industry is expected to grow in countries like the People’s Republic of China  
with their expanding middle class in emerging markets
4 0.1 0.4
Significant export potential to the developing as well as developed countries 5 0.05 0.25
existence of clear visions, objectives and strategies for the future 5 0.08 0.4
Development of existing and new clusters in the field of the medical device industry 2 0.07 0.14
Increased accessibility of risk capital sources for financing companies’ developmental activities 2 0.1 0.2
Purpose-oriented financing of science and research 4 0.1 0.4
Coordination of scientific research institutes 4 0.15 0.6
Coordination and unification of law related to the medical device industry 4 0.15 0.6
Total 1
Threats
Continuing stagnation of the eU economy 3 0.1 0.3
Financial and time difficulties involved in the development of innovative medical devices 3 0.08 0.24
Underestimated significance of marketing for entering foreign markets 4 0.1 0.4
Underrated R&D cooperation in clusters 3 0.1 0.3
A lack of workplaces with efficient systems for transferring science and research results 3 0.18 0.54
Preference given to short-term development goals 5 0.15 0.75
Little use of cooperation and connections among universities, scientific research institutes  
and institutions supporting innovative entrepreneurship capacities
5 0.17 0.85
Total 1
Notes: Criterion of each item on the scale from 1 to 5. The total impact column was created as the product of “Criteria*Significance”.
Abbreviations: eU, european Union; R&D, research and development. 
countries. objectives and strategies. Last but not least, also 
the unification and clarification of legislative requirements.
Discussion
The results from the aforementioned SWOT analysis can 
be compared with similar studies7,15,27,28 carried out in this 
sector in advanced and emerging economies as well as in 
the European and non-European countries (Table 3). The 
studies of the chosen economics such as the USA, the UK, 
or Israel describe current situation of the medical device 
industry in the developed countries. The opportunities and 
threats are completely different in comparison with studies 
of the emerging countries such as Mexico, Turkey, or the 
People’s Republic of China.
Table 3 summarizes SWOT analysis items for both 
developed and developing countries. The third column 
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contains information from the authors’ SWOT analysis of 
the European medical device industry. This analysis corre-
sponds to the results of studies in the developed countries. 
At the same time, it determines other significant items that 
are mentioned in the third column. The results of the authors’ 
study that correspond to the results of the SWOT analyses for 
developed countries are not listed in the third column.
There is a clear consensus if the results of the current analy-
sis of the European medical device industry are compared with 
the analyses of the developed countries. The opportunities such 
as aging global population, new health care system reform, 
international demand, and penetration into new markets. The 
threats of the medical device market in the developed countries, 
including the European countries, are global financial crisis, 
strong competition, customer bargaining power, and regula-
tory environment. The strengths perceived in the present day 
in advanced economies are powerful brands, strong R&D 
capability, large numbers of patents, and licensed production. 
The weaknesses common to advanced economies, which 
can be found in the aforementioned studies, as well as in the 
results of this study, are the quality management deficiency, 
large scale of investment, and fixed poor financial managing 
ability. In comparison with the developing economies, the lack 
of human capital is found in advanced economies and the lack 
of aggregate supply and demand.
The individual items of SWOT analysis were evaluated 
and assessed according to the importance by a team of profes-
sionals engaged in this area. Consequently, not only aspects 
of SWOT analysis that are associated with the develop-
ment of basic economic indicators were described, but also 
cooperative aspects of universities, scientific research insti-
tutes, and institutions supporting innovative entrepreneurship 
capacities were discussed. Unfortunately, the main findings 
show that there is little cooperation between scientific orga-
nizations and private sector, undervalued R&D cooperation 
in clusters, and preference given to short-term development 
goals. Other differences are listed in Table 3.
Conclusion
The medical device industry directly as well as indirectly, 
by ensuring better health of the population, influences the 
economic situations in each country.29,30 Moreover, despite 
the fact that the economic recession still continues in many 
countries, this industry is characterized by a slight growth. As 
far as its future development is concerned, the medical device 
industry may look for new opportunities for its development 
in the developed economies, and the expanding middle class 
in emerging nations, in aging population and more active T
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Figure 4 Financing among individual entities. 
seniors. The medical device industry will move with the 
general market and will grow moderately. On the other hand, 
there are several threats that should not be underrated as they 
may badly influence the medical device industry and worsen 
its competitiveness. For instance, global competition in 
world markets, low coordination of research activities within 
the EU, or complicated administrative procedures.
Experts are in wide agreement that advances in medical 
technology will fundamentally transform health care and deliv-
ery systems over the next decade by providing new solutions 
that will challenge existing paradigms and revolutionize the 
way treatments are administered. Critical elements in decision-
making about investments in developing new medical devices 
are the knowledge of market needs, awareness of benefits 
to society, and last but not least benefits for the health care 
system by decreasing expenditures on a given type of disease 
or condition. Figure 4 illustrates possible costs between the 
various entities. The primary payer for many types of medical 
device is the insurance company, not the patient.
In the future, the system for solving the investment assess-
ing in medical device development will be important in the 
future in the developed countries. Reasons are as follows:
•	 limited financial resources of governments in the developed 
countries and an effort to spend effectively on R&D,
•	 investments in the development and production of medi-
cal devices in relation to the growth of this market seems 
to be prospective in the private sector,
•	 a growing number of patients who live longer thanks to 
the high-quality health care.
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